April 16, 2026
Last Updated: April 2026
Asia-Pacific is not one market for CBD. It's five completely different legal environments stacked together, and making assumptions based on one country's rules when traveling or exporting to another can have serious consequences. The range here is dramatic: Japan recently reformed its hemp laws to allow compliant CBD. Hong Kong banned all cannabis derivatives including CBD. China produces most of the world's hemp but prohibits domestic CBD consumption.
| Country | CBD Legal? | THC Limit | Notes |
|---|---|---|---|
| China | ❌ Not for domestic consumption | N/A | Export allowed; cosmetic approval pathway |
| Hong Kong | ❌ Banned | N/A | 2023 ban includes all cannabis derivatives |
| Japan | ✅ Legal (with conditions) | 0% detectable | Hemp law reform 2023; strict THC enforcement |
| South Korea | ⚠️ Limited | Near-zero | Medical only; very restricted |
| India | ⚠️ State-dependent | N/A | Ayurvedic framework; patchwork regulation |
China produces approximately 50% of the world's legal hemp and is a major supplier of CBD isolate and hemp extracts to global markets. The irony is that these products are almost entirely for export — the Chinese government prohibits domestic consumption of CBD, classifying it under its drug control framework. A Chinese CBD manufacturer can legally produce and export CBD to the United States or Europe but cannot legally sell that product to Chinese consumers.
The one exception to China's domestic CBD prohibition is cosmetic products. The National Medical Products Administration (NMPA) has established an approval pathway for CBD-containing cosmetics. The NMPA process requires: pre-market safety assessment, ingredient registration, and manufacturing facility compliance. The pathway is available but not simple — it requires local regulatory expertise and a meaningful compliance investment.
No. Hong Kong banned all cannabis derivatives, including CBD, in February 2023. The amendment to the Dangerous Drugs Ordinance removed the previous regulatory gray zone that had allowed CBD products to be sold. The Hong Kong government's position is unambiguous: CBD is derived from cannabis, cannabis is a dangerous drug, and therefore CBD is a dangerous drug. There is no THC threshold, no hemp exception, and no approved pathway for CBD consumer products in Hong Kong. Do not bring CBD products into Hong Kong. This applies to CBD oil, CBD gummies, CBD topicals, and any other product containing CBD.
Japan's relationship with hemp and CBD underwent significant reform in 2023 with revisions to the Cannabis Control Act. The key change: Japan shifted from regulating the hemp plant itself to regulating THC content specifically. Under the reformed law, CBD products are legal in Japan provided they contain zero detectable THC. This is a stricter standard than the European 0.3% or the U.S. federal standard — Japanese testing equipment must confirm no detectable THC at all. Most U.S. full-spectrum CBD products do not meet Japanese requirements.
Brands exporting CBD to Japan must: use products with certified non-detectable THC from ISO-accredited labs, ensure labels and claims comply with Japanese consumer protection law (no health claims), register products with the appropriate Japanese regulatory authorities, and maintain documentation of the full supply chain from hemp cultivation to finished product.
South Korea has a very restricted CBD framework. CBD-based pharmaceuticals can be prescribed by doctors, but the consumer CBD market that exists in North America and Europe is effectively absent. Personal importation of CBD for medical purposes requires prior approval from the Ministry of Food and Drug Safety. Recreational or wellness-use CBD has no legal pathway in South Korea as of 2026.
India's CBD legal framework is an unresolved patchwork. The Narcotic Drugs and Psychotropic Substances Act categorizes cannabis broadly, but hemp has increasingly been recognized as distinct under the Ayurvedic and traditional medicine framework that some Indian states have used to permit hemp-derived products. Several Indian states have approved hemp cultivation and processing. But there's no national framework providing clear legal authorization for CBD consumer products, and enforcement varies dramatically between states and even cities. India is a market with enormous potential that is several years away from regulatory clarity.
Not for domestic consumption. China permits hemp production and CBD export but classifies CBD as a controlled substance for domestic use. CBD cosmetics have a NMPA approval pathway.
No. Hong Kong banned all cannabis derivatives including CBD in February 2023. Bringing CBD products into Hong Kong creates serious criminal legal exposure.
Yes, with strict conditions. CBD products must contain zero detectable THC. Most U.S. full-spectrum products don't qualify. CBD isolate and certified broad-spectrum products meeting Japan's standards are legal.
Highly restricted. CBD pharmaceuticals can be prescribed; consumer CBD has no legal pathway. Not a viable market for international CBD brands without significant regulatory change.
For consumer products, no. For cosmetic products, NMPA pre-approval is required. For industrial hemp raw materials for export-oriented manufacturing, yes with appropriate licensing.
